Mads Hald Andersen

Title: Mads Hald Andersen: Innovator in Immunotherapy

Introduction

Mads Hald Andersen, an accomplished inventor based in Nærum, Denmark, has made significant contributions to the field of immunotherapy, evidenced by his 23 patents. His innovative work focuses primarily on the development of novel polypeptides and immunotherapeutic strategies aimed at combating cancer.

Latest Patents

Among his latest patents is the invention titled "Immunogenic Arginase 2 Polypeptides." This invention relates to new polypeptides derived from Arginase 2, exploring their potential uses and applications in therapeutic compositions. Another notable patent is geared towards cancer treatment, titled "Indoleamine 2,3-Dioxygenase Based Immunotherapy." This invention encompasses IDO or its peptide fragments that are capable of inducing anti-cancer immune responses. It highlights the use of IDO-specific T-cells for treating cancer, and discusses the combination of this therapy with existing cancer chemotherapy treatments. Additionally, this work addresses the prophylaxis and therapy of infections through similar mechanisms.

Career Highlights

Mads has worked with prominent companies in the biotechnology sector, including Io Biotech ApS and Survac ApS. His experience within these organizations has enabled him to refine his research and drive forward his innovative ideas in therapeutic treatments.

Collaborations

Throughout his career, Mads has collaborated with leading professionals in his field. Noteworthy among his coworkers are Per Thor Straten and Eivind Per Thor Straten, who have both contributed significantly to the advancements in cancer immunotherapies alongside him.

Conclusion

In summary, Mads Hald Andersen's contributions to immunotherapy through his patents underscore his role as a transformative inventor in the medical field. His ongoing work continues to pave the way for new and effective treatments against cancer and infectious diseases.